• Molecular NameLenalidomide
  • SynonymCC-5013; CDC 501; IMiD3; lenalidomide
  • Weight259.265
  • Drugbank_IDDB00480
  • ACS_NO191732-72-6
  • Show 2D model
  • LogP (experiment)-0.318
  • LogP (predicted, AB/LogP v2.0)0.43
  • pkaN/A
  • LogD (pH=7, predicted)0.41
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.13
  • LogSw (predicted, AB/LogsW2.0)1.14
  • Sw (mg/ml) (predicted, ACD/Labs)19.32
  • No.of HBond Donors3
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds1
  • TPSA92.5
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS).
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding30.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmUndetermined
  • Half life3 h
  • ExcretionRenal (67% unchanged)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A